ADAR2 Antibody (1.3.1): sc-73409

ADAR2 Antibody (1.3.1) is a mouse monoclonal IgG1 kappa light chain antibody that detects ADAR2 in mouse, rat, and human samples by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Anti-ADAR2 antibody (1.3.1) is available in non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. ADAR2, also known as adenosine deaminase, RNA-specific (RED1), plays a crucial role in RNA editing by converting adenosine to inosine, which is essential for proper nervous system function. ADAR2 is particularly important for editing pre-mRNA of glutamate receptor subunit B, allowing generation of new splice sites and modification of its own pre-mRNA, thereby influencing protein isoform diversity. ADAR2′s ability to move from nucleolus to nucleoplasm enhances editing activity on endogenous substrates, maintaining neuronal excitability and synaptic plasticity. Alternative splicing of ADAR2 results in several transcript variants, which may further modulate RNA editing processes. ADAR2′s significance in post-transcriptional regulation highlights potential therapeutic applications in neurological disorders with disrupted RNA editing.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ADAR2 Antibody (1.3.1) References:

1. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2.  |  Higuchi, M., et al. 2000. Nature. 406: 78-81. PMID: 10894545
2. Substrate recognition by ADAR1 and ADAR2.  |  Wong, SK., et al. 2001. RNA. 7: 846-58. PMID: 11421361
3. ADAR2 A-->I editing: site selectivity and editing efficiency are separate events.  |  Källman, AM., et al. 2003. Nucleic Acids Res. 31: 4874-81. PMID: 12907730
4. Modulation of RNA editing by functional nucleolar sequestration of ADAR2.  |  Sansam, CL., et al. 2003. Proc Natl Acad Sci U S A. 100: 14018-23. PMID: 14612560
5. Structure and sequence determinants required for the RNA editing of ADAR2 substrates.  |  Dawson, TR., et al. 2004. J Biol Chem. 279: 4941-51. PMID: 14660658
6. ADAR2-mediated editing of RNA substrates in the nucleolus is inhibited by C/D small nucleolar RNAs.  |  Vitali, P., et al. 2005. J Cell Biol. 169: 745-53. PMID: 15939761
7. Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing.  |  Macbeth, MR., et al. 2005. Science. 309: 1534-9. PMID: 16141067
8. Altered RNA editing in mice lacking ADAR2 autoregulation.  |  Feng, Y., et al. 2006. Mol Cell Biol. 26: 480-8. PMID: 16382140
9. ADAR2 increases in exercised heart and protects against myocardial infarction and doxorubicin-induced cardiotoxicity.  |  Wu, X., et al. 2022. Mol Ther. 30: 400-414. PMID: 34274534
10. Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis.  |  Guo, M., et al. 2023. Blood. 141: 3078-3090. PMID: 36796022
11. The RNA editor ADAR2 promotes immune cell trafficking by enhancing endothelial responses to interleukin-6 during sterile inflammation.  |  Gatsiou, A., et al. 2023. Immunity. 56: 979-997.e11. PMID: 37100060
12. ADAR2 deficiency ameliorates non-alcoholic fatty liver disease and muscle atrophy through modulating serum amyloid A1.  |  Kung, ML., et al. 2024. J Cachexia Sarcopenia Muscle. 15: 949-962. PMID: 38533529

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-ADAR2 Antibody (1.3.1) has 30 citations in a variety of scientific publications.

Primary antibodies like Anti-ADAR2 Antibody (1.3.1) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

ADAR2 Antibody (1.3.1) Specifications

Alternate Product Name: ADAR2

Product Clone Name: 1.3.1

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 2-179

Epitope Target: ADAR2

Epitope Species: human

Product Reactivity/Detection: native and recombinant ADAR2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 30 citations in various scientific publications

Available Conjugates/Forms for ADAR2 Antibody (1.3.1): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin